Patient Support

Enroll eligible patients and learn more about a range of access resources and support services

For reimbursement support, contact R-Pharm US Access and Support in one of the following ways:

Call the Support Center at 1-855-991-7277, 8 AM to 8 PM ET, Monday through Friday

Fax the Support Center at 1-877-541-7813

Download and complete the forms as directed below:

R-Pharm US Access and Support enrollment form

Fill out this form with the help of your doctor or nurse to enroll in the R-Pharm US Access and Support program. This program offers helpful access and support resources. It can help review what benefits are covered under your plan for R-Pharm US medicines. It can also assist with the cost of your medicine if you have no active insurance.

R-Pharm US Access and Support patient authorization form

Fill out this form to allow the R-Pharm US Access and Support program to provide you with services and assistance. This form should be used only if you filled out an R-Pharm US Access and Support enrollment form but did not sign it.

The information provided is intended for use by individuals involved with reimbursement support.

The accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and patient. R-Pharm US and its agents make no guarantee regarding reimbursement for any service or item.

Indications and Important Safety Informationexpand

Important Safety Information
WARNING: Toxicity in hepatic impairment

Contraindications

Peripheral neuropathy

Myelosuppression

Hypersensitivity reaction

Pregnancy

Cardiac adverse reactions

Potential for cognitive impairment from excipients

Adverse reactions

Monotherapy

Combination with capecitabine

Cremophor is a registered trademark of BASF AG.

AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; CTC = common terminology criteria.

Indications

IXEMPRA® (ixabepilone) is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

  • Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting
  • Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting

IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

Please see US Full Prescribing Information, including boxed WARNING regarding hepatic impairment.

Medical information

For product information or to report an adverse reaction, please call 1-888-493-6772 or e-mail DrugSafety@propharmagroup.com.

This site is intended for US healthcare professionals.

The R-Pharm US Access and Support logo is a trademark and IXEMPRA® is a registered trademark of R-Pharm US Operating LLC, a wholly owned subsidiary of R-Pharm US LLC.

© 2021, R-PHARM US. All rights reserved. IXE-00096-02   08/16

Please verify if you are a US healthcare professional